나노의약품 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 형태별, 용도별, 지역별 세분화 및 경쟁 구도(2020-2030년)
Nanopharmaceuticals Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Form, By Application, By Region and Competition, 2020-2030F
상품코드:1879175
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 나노의약품 시장은 2024년에 596억 8,000만 달러로 평가되었고, 2030년까지 연평균 복합 성장률(CAGR) 9.80%로 성장하여 1,045억 8,000만 달러에 이를 것으로 예측됩니다.
나노의약품은 나노기술을 활용하여 치료제의 전달성, 표적화, 유효성을 높인 의약품의 일종으로, 일반적으로 나노 스케일(1-100나노미터)로 제형화하여 용해도, 안정성, 생체 이용률을 높인 의약품을 말합니다. 시장 확대는 주로 표적화된 보다 효과적인 치료법을 필요로 하는 만성질환 증가와 재생의료 및 나노기술 기반 의약품 개발에 대한 정부 및 민간 자금 증가에 의해 주도되고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
596억 8,000만 달러
시장 규모 : 2030년
1,045억 8,000만 달러
CAGR : 2025-2030년
9.8%
성장 속도가 가장 빠른 부문
리포솜
최대 시장
북미
주요 시장 성장 촉진요인
주요 시장 과제
주요 시장 동향
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 나노의약품 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
형태별(리포솜, 고분자 미셀, 고체 지질 나노입자, 마이크로 에멀전, 나노 에멀전, 나노 서스펜션, 기타)
용도별(임상 종양학, 감염증, 심혈관질환)
지역별
기업별(2024년)
시장 맵
제6장 북미의 나노의약품 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 나노의약품 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 나노의약품 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 나노의약품 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트(UAE)
남아프리카공화국
제10장 남미의 나노의약품 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병(M&A)
제품 출시
최근 동향
제13장 세계의 나노의약품 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Merck & Co., Inc.
Pfizer Inc.
Novartis AG
Abbott Laboratories Inc.
GlaxoSmithKline plc
Eli Lilly and Company
Johnson & Johnson(J&J)
Gilead Sciences, Inc.
AstraZeneca plc
Celgene Corporation
제16장 전략적 제안
제17장 회사 소개 및 면책조항
LSH
영문 목차
영문목차
The Global Nanopharmaceuticals Market, valued at USD 59.68 Billion in 2024, is projected to experience a CAGR of 9.80% to reach USD 104.58 Billion by 2030. Nanopharmaceuticals are a class of pharmaceutical drugs leveraging nanotechnology for enhanced therapeutic agent delivery, targeting, and efficacy, typically formulated at the nanoscale (1 to 100 nanometers) to improve solubility, stability, and bioavailability. The market's expansion is primarily driven by the increasing prevalence of chronic diseases demanding targeted and more effective treatment options, coupled with growing government and private funding in regenerative medicine and nanotechnology-based drug development.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 59.68 Billion
Market Size 2030
USD 104.58 Billion
CAGR 2025-2030
9.8%
Fastest Growing Segment
Liposomes
Largest Market
North America
Key Market Drivers
The rising prevalence of chronic diseases represents a profound market driver, fueling an urgent demand for advanced therapeutic solutions that surpass the limitations of conventional treatments. Global health challenges posed by conditions such as cancer, cardiovascular ailments, and neurological disorders necessitate therapies offering enhanced efficacy and reduced systemic burden. Nanopharmaceuticals directly address this need through targeted delivery and improved bioavailability, promising better patient outcomes.
Key Market Challenges
The nanopharmaceuticals market faces significant impediment from the high investments required for drug development and the complexities surrounding regulatory approvals for novel nanoscale therapeutics. These factors collectively contribute to prolonged development timelines and substantially increased costs, directly impeding widespread market adoption and commercialization. Developing nanopharmaceuticals demands extensive research and development to understand novel material properties, ensure safety, and demonstrate efficacy at the nanoscale.
Key Market Trends
The focus on personalized nanomedicine is driving advancements by tailoring treatments to individual patient profiles, moving beyond a one-size-fits-all approach. This customization allows for optimized therapeutic effects and reduced adverse reactions, particularly critical for complex diseases. For instance, according to Precision Nanomedicine for Cancer: Innovations, Strategies, and Translational Challenges, published October 2025, the formulation of anti-EpCAM aptamers has risen as an advanced tactic for precise conveyance of therapeutics to malignant tissues, demonstrating significant potential in preliminary research and clinical trials. This capability enhances treatment efficacy and patient outcomes by ensuring therapeutic agents are delivered with high specificity.
Key Market Players
Merck & Co., Inc.
Pfizer Inc.
Novartis AG
Abbott Laboratories Inc.
GlaxoSmithKline plc
Eli Lilly and Company
Johnson & Johnson (J&J)
Gilead Sciences, Inc.
AstraZeneca plc
Celgene Corporation
Report Scope:
In this report, the Global Nanopharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Nanopharmaceuticals Market, By Form:
Liposomes
Polymeric Micelles
Solid Lipid Nanoparticles
Microemulsion
Nanoemulsion
Nanosuspension
Others
Nanopharmaceuticals Market, By Application:
Clinical Oncology
Infectious Diseases
Cardiovascular Diseases
Nanopharmaceuticals Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Nanopharmaceuticals Market.
Available Customizations:
Global Nanopharmaceuticals Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Nanopharmaceuticals Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Form (Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion, Nanoemulsion, Nanosuspension, Others)
5.2.2. By Application (Clinical Oncology, Infectious Diseases, Cardiovascular Diseases)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Nanopharmaceuticals Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Form
6.2.2. By Application
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Nanopharmaceuticals Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Form
6.3.1.2.2. By Application
6.3.2. Canada Nanopharmaceuticals Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Form
6.3.2.2.2. By Application
6.3.3. Mexico Nanopharmaceuticals Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Form
6.3.3.2.2. By Application
7. Europe Nanopharmaceuticals Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Form
7.2.2. By Application
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Nanopharmaceuticals Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Form
7.3.1.2.2. By Application
7.3.2. France Nanopharmaceuticals Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Form
7.3.2.2.2. By Application
7.3.3. United Kingdom Nanopharmaceuticals Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Form
7.3.3.2.2. By Application
7.3.4. Italy Nanopharmaceuticals Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Form
7.3.4.2.2. By Application
7.3.5. Spain Nanopharmaceuticals Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Form
7.3.5.2.2. By Application
8. Asia Pacific Nanopharmaceuticals Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Form
8.2.2. By Application
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Nanopharmaceuticals Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Form
8.3.1.2.2. By Application
8.3.2. India Nanopharmaceuticals Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Form
8.3.2.2.2. By Application
8.3.3. Japan Nanopharmaceuticals Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Form
8.3.3.2.2. By Application
8.3.4. South Korea Nanopharmaceuticals Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Form
8.3.4.2.2. By Application
8.3.5. Australia Nanopharmaceuticals Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Form
8.3.5.2.2. By Application
9. Middle East & Africa Nanopharmaceuticals Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Form
9.2.2. By Application
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Nanopharmaceuticals Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Form
9.3.1.2.2. By Application
9.3.2. UAE Nanopharmaceuticals Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Form
9.3.2.2.2. By Application
9.3.3. South Africa Nanopharmaceuticals Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Form
9.3.3.2.2. By Application
10. South America Nanopharmaceuticals Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Form
10.2.2. By Application
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Nanopharmaceuticals Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Form
10.3.1.2.2. By Application
10.3.2. Colombia Nanopharmaceuticals Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Form
10.3.2.2.2. By Application
10.3.3. Argentina Nanopharmaceuticals Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Form
10.3.3.2.2. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Nanopharmaceuticals Market: SWOT Analysis
